Cambridge-based CN Bio, an organ-on-a-chip company that designs and manufactures single-and multi-organ microphysiological systems, has appointed Dr Samantha Macro as chief financial officer, tasked with guiding all key commercial and strategic initiatives, driving revenue, and shaping CN Bio’s growth.

Macro has financial industry experience, including more than 15 years in life sciences, Most recently, she was vice-president of finance at Mestag Therapeutics. Before that, she was global head of finance at Horizon Discovery. She has also held various leadership roles at the Johnson Matthey Pharma division, and across multiple innovative medicine units at AstraZeneca. Earlier, Macro qualified as a chartered accountant at PwC and held senior roles at PwC and Aviva.

Macro said: “CN Bio’s OOC solutions are disruptive within the sector, capable of accurately and efficiently predicting human responses to medicines. As its growing range of products and services continue to gain traction across global markets, I look forward to working closely with the leadership team and leveraging my commercial insight to push the company to reach its full potential.”

CN Bio’s chief executive Dr Paul Brooks, commented: “I look forward to working closely with Samantha, who brings great experience and will be a strong addition to CN Bio’s team. She has a proven track record in fundraising and will bring valuable M&A experience to the company. We have reached a critical phase in the commercialisation of our OOC technology, and Samantha will be instrumental in reaching our business goals and executing our continued growth strategy.”